■两种囊泡单胺转运蛋白2(VMAT2)抑制剂在美国(US)被批准用于治疗迟发性运动障碍(TD)。关于VMAT2抑制剂治疗对患者社会和身体健康的影响的信息很少。该研究的目的是阐明临床医生报告的症状改善以及接受VMAT2抑制剂的患者的社会或身体健康的任何明显变化。
■向医生提供了基于网络的调查，执业护士,以及在过去24个月内为TD开缬草嗪的美国医师助理。临床医生报告了符合纳入标准并被允许回忆缺失信息的患者图表中的数据。
■受访者包括163名临床医生，他们查看了601名VMAT2治疗的TD患者的图表：47％的患者在≥2个身体区域出现TD症状，最常见的是头部或面部和上肢。治疗前,93%的患者表现出≥1个社会领域的障碍，88%的患者在≥1个物理领域受损。治疗后,在TD症状改善的患者中（n=540），80%到95%的人在社会领域有所改善，90％至95％显示物理领域的改善，73%的人的主要精神状况有所改善。
■在用VMAT2治疗的TD症状改善的患者中，临床医生报告称,精神疾病症状以及社会和身体健康也随之改善.在评估VMAT2抑制剂治疗的价值时，定期评估TD对这些类型领域的影响应与运动障碍评级同时进行。
UNASSIGNED: Two vesicular monoamine transporter 2 (VMAT2) inhibitors are approved in the United States (US) for the treatment of tardive dyskinesia (TD). There is a paucity of information on the impact of VMAT2 inhibitor treatment on patient social and physical well-being. The study objective was to elucidate clinician-reported improvement in symptoms and any noticeable changes in social or physical well-being in patients receiving VMAT2 inhibitors.
UNASSIGNED: A web-based survey was offered to physicians, nurse practitioners, and physician assistants based in the US who prescribed valbenazine for TD within the past 24 months. Clinicians reported data from the charts of patients who met the inclusion criteria and were allowed to recall missing information.
UNASSIGNED: Respondents included 163 clinicians who reviewed charts of 601 VMAT2-treated patients with TD: 47% had TD symptoms in ≥2 body regions, with the most common being in the head or face and upper extremities. Prior to treatment, 93% of patients showed impairment in ≥1 social domain, and 88% were impaired in ≥1 physical domain. Following treatment, among those with improvement in TD symptoms (n = 540), 80% to 95% showed improvement in social domains, 90% to 95% showed improvement in physical domains, and 73% showed improvement in their primary psychiatric condition.
UNASSIGNED: In VMAT2-treated patients with TD symptom improvement, clinicians reported concomitant improvement in psychiatric disorder symptoms and in social and physical well-being. Regular assessment of TD impact on these types of domains should occur simultaneously with movement disorder ratings when evaluating the value of VMAT2 inhibitor therapy.
PDF(Pubmed)